Australia is poised to receive Retatrutide, a dual-action GLP-1 target drug created by Novo Nordisk. Early trial findings suggest it could offer significant outcomes for people facing weight-related issues. Beyond https://kaitlynuzsq080426.mappywiki.com/2626268/this_new_drug_retatrutide_australia_a_promising_hope_for_body_loss